Pyxis Oncology Announces Updated Data From Ongoing Global Phase 1 Monotherapy Study Evaluating Micvotabart Pelidotin In Patients With 2L+ R/M Head And Neck Squamous Cell Carcinoma
MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment
Pyxis tested a new cancer medicine and found it worked well in many patients—36% had tumors shrink, and 94% saw their disease stop getting worse. When a medicine shows strong results like this, people watch to see if it could become real help for patients and valuable for the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.